Stockwinners Market Radar for April 07, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:28 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Fiat Chrysler (FCAU) has agreed to pay Tesla (TSLA) hundreds of millions of euros to allow the electric carmaker's vehicles to be counted in its fleet to avoid fines for violating new EU emission rules, Financial Times' Patrick McGee and Peter Campbell reported. The move will allow Fiat Chrysler to offset CO2 emissions from its cars against Tesla's, lowering its average figure to a permissible level, the publication added. 2. Hyundai Motor (HYMTF) denied it had signed a preliminary deal with Tencent (TCEHY) to develop software for driverless vehicles, according to Reuters. Hyundai's comments come a day after South Korea's Maeil Business Newspaper cited unnamed industry sources saying that the two companies planned to conduct joint research and development on safety and security systems for self-driving cars, which Hyundai seeks to roll out commercially by 2030, the report added. 3. Congress legalized hemp and its soothing extract cannabidiol, or CBD, and now the stock market cannot get enough of the stuff, Bill Alpert wrote in this week's edition of Barron's. Cannabis producers like Canopy Growth (CGC), Aurora Cannabis (ACB) and Tilray (TLRY) quickly got into hemp and the stocks of companies that have long bet their business on CBD have doubled in recent months, including Charlotte's Web (CWBHF) and GW Pharmaceuticals (GWPH), he noted. Unfortunately, there are no bargains among hemp or marijuana stocks these days, the author contended. 4. AT&T (T) subsidiary Warner Bros' "Shazam!" easily won the weekend box office with $53.5M from 4,217 theaters. Overseas, the kid-friendly movie is also off to a strong start, earning $102M from 79 markets for a global weekend haul of $155.5M. The pic sports an A CinemaScore and a 91% Rotten Tomatoes score. 5. Foot Locker (FL) saw a positive mention in Barron's.

17:01 EDT Box Office Battle: 'Shazam!' wins weekend with $53.5M - AT&T (T) subsidiary Warner Bros' "Shazam!" easily won the weekend box office with $53.5M from 4,217 theaters. Overseas, the kid-friendly movie is also off to a strong start, earning $102M from 79 markets for a global weekend haul of $155.5M. The pic sports an A CinemaScore and a 91% Rotten Tomatoes score. BOX OFFICE RUNNERS-UP: Viacom (VIAB) subsidiary Paramount's "Pet Sematary" debuted at number 2 with $25M from 2,585 locations. Behind was Disney's (DIS) "Dumbo," earning $18.2M in its second weekend for a disappointing 10-day domestic total of $76.3M. Comcast (CMCSA, CMCSK) subsidiary Universal's "Us" placed number four, crossing the $100M mark globally in its third weekend after earning another $13.8M domestically. Rounding out the top five, Marvell and Walt Disney Studio's "Captain Marvell" grossed an estimated $12.7M in its fifth weekend for a total of $374.1M. Other publicly traded companies in filmmaking include Lionsgate's (LGF.A) and Sony (SNE).

12:13 EDT Amgen presents new data revealing Osteoporosis treatment gap in Europe - Amgen announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in Europe. The real-world study of osteoporosis management in primary care revealed that 75% of female patients aged 70 years and older who were at increased risk of fragility fractures were not treated for osteoporosis. The treatment gap was much lower in those with a recorded diagnosis of osteoporosis than in those without a recorded diagnosis. The results of the study, which was performed across eight European countries, were presented during the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, in Paris from April 4-7, 2019. The study enrolled 3,798 women aged 70 years or older after spontaneously visiting their primary care physician for any reason, not specifically related to their bone health. The primary outcome of the study was to assess the proportion of patients at increased risk of fragility fracture who were not receiving osteoporosis medication. Nearly 55% of patients were considered to be at increased risk of fragility fracture, with 75% of them not being medically treated for osteoporosis. Further, the study showed that among these untreated patients at risk for fracture, 85% had no recorded diagnosis of osteoporosis.